STJ ST. Jude Medical, Inc.

St. Jude Medical, Inc. (NYSE:STJ) today announced the first patient implants in a clinical study that is investigating whether deep brain stimulation (DBS) therapy will help people who suffer from major depressive disorder, a severe form of depression. The patients, a 59-year-old woman and a 42-year-old man, were implanted at Alexian Brothers Behavioral Health Hospital in Chicago, with the St. Jude Medical Libra� Deep Brain Stimulation System, an investigational device. The study, called BROADEN� (BROdmann Area 25 DEep brain Neuromodulation), is a controlled, multi-site, blinded study that is evaluating the safety and effectiveness of DBS in patients with depression for whom currently available treatments are not effective. �We are excited to be part of the first double-blind study of Deep Brain Stimulation for depression and remain hopeful that this therapy may prove beneficial for this seriously ill patient population,� said Anthony D'Agostino, M.D., medical director of Alexian Brothers Behavioral Health Hospital and the principal investigator at the study site. �The study is an important contribution to the advancement of treatment options for severely depressed patients.� This study is researching a specific area in the brain called Brodmann Area 25 that is thought to be involved in depression. The first research of DBS for depression was conducted in Toronto, Canada, by neurologist Helen S. Mayberg, M.D., and neurosurgeon Andres Lozano, M.D., in 2003. They published their findings in Neuron in March 2005, reporting that brain imaging studies indicate that Brodmann Area 25 appears to be overactive in profoundly sad and depressed people. St. Jude Medical owns the intellectual property rights, and has various patents issued and pending, for the use of neurostimulation at Brodmann Area 25. The Libra Deep Brain Stimulation System provides mild pulses of current from a device implanted near the collarbone and connected to small electrical leads placed at specific targets in the brain. �This depression study represents a continuation of our commitment to provide solutions for those who are suffering and in need of additional therapy options,� said Chris Chavez, president of the St. Jude Medical ANS Division. �The Brodmann Area 25 study is an important step in bringing physicians and their patients a neuromodulation therapy that, if successful, will treat this debilitating form of depression.� The National Institute of Mental Health estimates that more than 21�million U.S. adults suffer from some kind of depressive disorder. Current therapies are effective for about 80 percent of this patient population according to the National Advisory Mental Health Council. That means approximately 4�million adult Americans live with depression that doesn�t respond to medications, psychotherapy or electroconvulsive therapy. To be eligible for this study, participants must: Currently be diagnosed with major depressive disorder Be between 21 and 70 years old, with onset of first episode before age 45 Have tried at least four treatments in their current episode, such as different medications, various combinations of medications or electroconvulsive therapy Have been depressed for at least one year For more information about this study, call toll-free at 866-787-4332, visit www.BROADENstudy.com. Sponsored by St. Jude Medical, the BROADEN study is being conducted under a U.S. Food and Drug Administration (FDA) investigational device exemption (IDE). Initial study centers are located in Chicago, Dallas and New York City. This clinical study was preceded by a smaller pilot study of 20 patients at three sites in Canada which found that six months after the procedure, 56 percent of the patients experienced at least a 40 percent decrease in depressive symptoms. At last follow-up, 78 percent of the patients were responders, and eight of the patients have re-engaged in life activities such as work, school, travel and relationships, and three of the study patients are considered to be in remission. Patients� symptoms were measured using the Hamilton Rating Scale for Depression. About St. Jude Medical St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 12,000 people worldwide and has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. For more information, please visit www.sjm.com. About the ANS Division of St. Jude Medical The ANS Division (Advanced Neuromodulation Systems) became a part of St. Jude Medical in 2005. The ANS Division is an innovative technology leader dedicated to the design, development, manufacturing and marketing of implantable neuromodulation systems to improve the quality of life for people suffering from disabling chronic pain and other nervous system disorders (www.ans-medical.com). Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings, and market shares. The statements made by the Company are based upon management�s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company�s control and the risk factors and other cautionary statements described in the Company�s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company�s Annual Report on Form 10-K filed on February 27, 2008. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.